Skip to main content

Table 1 Expression levels of six potential biomarkers in patients with high-risk prostate cancer who underwent radical prostatectomy with and without neoadjuvant treatment

From: Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer

     NNA NHT CHT p-value p value (NNA vs. CHT) p value (NHT vs. CHT)
AR Epithelial cells Nuclear Area 3.01 ± 0.10 2.06 ± 0.13 2.07 ± 0.0.06 < 0.001 < 0.001 0.984
   Intensity 2.27 ± 0.08 1.94 ± 0.12 1.79 ± 0.05 < 0.001 < 0.001 0.208
   Immunoreactivity score 7.20 ± 0.39 4.50 ± 0.40 4.16 ± 0.18 < 0.001 < 0.001 0.441
  Cytoplasmic Potitive/Negative (% of positive) 60/22 (73.2%) 48/16 (75.0%) 82/162 (33.6%) < 0.001 < 0.001 < 0.001
Stromal cells   Area 1.21 ± 0.65 1.72 ± 0.81 1.55 ± 0.64 < 0.001 < 0.001 0.077
   Intensity 1.08 ± 0.06 1.50 ± 0.08 1.33 ± 0.04 < 0.001 < 0.001 0.034
   Immunoreactivity score 1.54 ± 0.14 2.94 ± 0.24 2.26 ± 0.10 < 0.001 < 0.001 0.010
GR Epithelial cells Nuclear Area 1.80 ± 0.10 1.69 ± 0.13 2.36 ± 0.05 < 0.001 < 0.001 < 0.001
   Intensity 1.55 ± 0.10 1.66 ± 0.12 1.88 ± 0.06 0.009 0.004 0.076
   Immunoreactivity score 3.35 ± 0.29 3.38 ± 0.37 4.83 ± 0.20 < 0.001 < 0.001 0.001
  Cytoplasmic Potitive/Negative (% of positive) 0/80 (0%) 0/64 (0%) 38/196 (16.2%) < 0.001 < 0.001 0.001
Stromal cells   Area 1.92 ± 0.07 1.78 ± 0.06 1.77 ± 0.05 0.180 0.055 0.875
   Intensity 2.82 ± 0.02 2.88 ± 0.04 2.92 ± 0.03 0.133 0.049 0.396
   Immunoreactivity score 5.41 ± 0.20 5.13 ± 0.19 5.23 ± 0.14 0.663 0.452 0.672
ERα Stromal cells Nuclear Area 0.73 ± 0.08 1.13 ± 0.11 1.24 ± 007 < 0.001 < 0.001 0.392
   Intensity 0.65 ± 0.07 1.19 ± 0.12 1.32 ± 0.07 < 0.001 < 0.001 0.391
   Immunoreactivity score 0.85 ± 0.11 1.97 ± 0.25 2.51 ± 0.17 < 0.001 < 0.001 0.074
PR Epithelial cells Cytoplasmic Area 0.82 ± 0.08 0.28 ± 0.07 0.30 ± 0.04 < 0.001 < 0.001 0.808
   Intensity 1.54 ± 0.14 0.38 ± 0.09 0.52 ± 0.06 < 0.001 < 0.001 0.197
   Immunoreactivity score 1.82 ± 0.20 0.50 ± 0.14 0.63 ± 0.08 < 0.001 < 0.001 0.455
Stromal cells Nuclear Area 1.13 ± 0.06 1.56 ± 0.09 2.30 ± 0.04 < 0.001 < 0.001 < 0.001
   Intensity 2.24 ± 0.11 2.47 ± 0.09 2.94 ± 0.02 < 0.001 < 0.001 < 0.001
   Immunoreactivity score 2.85 ± 0.19 3.75 ± 0.24 6.76 ± 0.14 < 0.001 < 0.001 < 0.001
MOB4A Epithelial cells Cytoplasmic Area 2.21 ± 0.13 2.06 ± 0.15 2.63 ± 0.05 < 0.001 0.002 0.001
   Intensity 1.09 ± 0.08 1.20 ± 0.11 1.49 ± 0.04 < 0.001 < 0.001 0.014
   Immunoreactivity score 2.93 ± 0.24 3.20 ± 0.31 4.09 ± 0.13 < 0.001 < 0.001 0.004
YAP1 Epithelial cells Nuclear Area 1.54 ± 0.09 1.27 ± 0.15 1.76 ± 0.06 < 0.001 0.048 0.002
   Intensity 1.68 ± 0.11 1.27 ± 0.15 1.78 ± 0.05 < 0.001 0.377 0.002
   Immunoreactivity score 3.03 ± 0.24 2.83 ± 0.42 3.55 ± 0.17 0.086 0.104 0.113
  Cytoplasmic Area 1.95 ± 0.12 1.73 ± 0.14 2.42 ± 0.06 < 0.001 < 0.001 < 0.001
   Intensity 1.14 ± 0.05 1.23 ± 0.08 1.73 ± 0.11 < 0.001 < 0.001 < 0.001
   Immunoreactivity score 2.57 ± 0.26 2.90 ± 0.32 4.71 ± 0.20 < 0.001 < 0.001 < 0.001
  1. NNA no neoadjuvant threatment, NHT neoadjuvant hormonal therapy, CHT neoadjuvant chemohormonal therapy, AR androgen receptor, GR glucocorticoid receptor, ER estrogen receptor, PR progesterone receptor
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us